Verastem Inc reports results for the quarter ended June 30 - Earnings Summary

• Verastem Inc VSTM.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of nine analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -99 cents to -56 cents per share.

• Revenue fell 78.6% to $2.14 million from a year ago; analysts expected $1.12 million.

• Verastem Inc's reported EPS for the quarter was a loss of 62 cents​.

• Verastem Inc shares had risen by 37.8% this quarter and gained 10.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Verastem Inc is $14.00, about 59.9% above its last closing price of $5.62

This summary was machine generated from LSEG data August 8 at 03:11 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)